Condition: Liver Transplantation · Immune Tolerance · Immune Tolerance/Drug Effects · Sponsor: University of California, Los Angeles
This clinical trial is being conducted to help liver transplant recipients safely discontinue toxic immunosuppressive drugs years after surgery. Lifelong use of these drugs is the current standard, but they come with life-threatening side effects. UCLA has pioneered this "Delayed Tolerance" approach, achieving success in numerous kidney recipients now living drug-free. The process uses a conditioning regimen followed by donor stem cell infusion to retrain the immune system to accept the liver as "self."
This description comes directly from the study's public registry record.
Cray V. Noah, MD · 310-267-7727 · cnoah@mednet.ucla.edu
Ruth Jones · 424-402-9564 · tolerance@mednet.ucla.edu
Always discuss trial participation with your own doctor first.
| UCLA Health 200 Medical Plaza | Los Angeles, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07269041